HC Wainwright Reiterates Buy Rating for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 239.51% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Leerink Partners started coverage on MannKind in a report on Thursday, November 13th. They set an “outperform” rating and a $7.00 target price for the company. Zacks Research cut MannKind from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 10th. Truist Financial set a $9.00 target price on MannKind in a research report on Monday, November 24th. Royal Bank Of Canada cut their target price on MannKind from $8.00 to $7.50 and set an “outperform” rating on the stock in a research note on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of MannKind in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.93.

MannKind Stock Performance

Shares of MNKD stock opened at $3.24 on Wednesday. MannKind has a 52 week low of $2.93 and a 52 week high of $6.51. The company’s 50 day moving average price is $5.61 and its two-hundred day moving average price is $5.35. The company has a market capitalization of $994.91 million, a P/E ratio of 32.40 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a negative return on equity of 49.33% and a net margin of 9.32%.The company had revenue of $111.96 million for the quarter, compared to the consensus estimate of $99.85 million. During the same period in the prior year, the company earned $0.03 EPS. The firm’s revenue was up 45.8% on a year-over-year basis. Analysts forecast that MannKind will post 0.1 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michael Castagna sold 65,804 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.01, for a total value of $395,482.04. Following the sale, the chief executive officer owned 2,504,792 shares in the company, valued at approximately $15,053,799.92. This represents a 2.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the sale, the insider directly owned 985,007 shares of the company’s stock, valued at $6,235,094.31. This represents a 4.55% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 262,846 shares of company stock valued at $1,546,840. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On MannKind

Several large investors have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV acquired a new stake in shares of MannKind during the 4th quarter worth about $70,000. Voloridge Investment Management LLC raised its holdings in MannKind by 50.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,861,046 shares of the biopharmaceutical company’s stock valued at $10,552,000 after acquiring an additional 626,878 shares during the period. Tudor Investment Corp ET AL acquired a new stake in MannKind during the fourth quarter worth approximately $182,000. Polymer Capital Management US LLC acquired a new stake in MannKind during the fourth quarter worth approximately $168,000. Finally, Man Group plc boosted its holdings in shares of MannKind by 80.9% during the fourth quarter. Man Group plc now owns 178,494 shares of the biopharmaceutical company’s stock worth $1,012,000 after acquiring an additional 79,843 shares during the period. 49.55% of the stock is owned by institutional investors.

MannKind News Roundup

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue and commercial momentum — Q4 revenue came in ~$112M, up ~46% year-over-year, with Furoscix net sales up ~91% and management outlining a ~$450M 2026 revenue run‑rate plus Afrezza pediatric launch plans as upcoming catalysts. Company Press Release Run‑rate / Afrezza article
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a Buy rating and an $11 price target, signaling upside potential for some investors. Analyst note
• Positive Sentiment: Bullish options activity — unusually large call buying was reported ahead of results, which can reflect institutional/speculative interest in upside. (No direct article link available.)
• Neutral Sentiment: Earnings call materials available — full Q4 2025 earnings call transcript and slide deck were published for investors to review management’s commentary and guidance. Earnings transcript
• Negative Sentiment: EPS miss / unexpected loss — MannKind reported a ($0.05) EPS vs. the consensus loss of ($0.01), an earnings miss that drove immediate downside despite the revenue beat. Why stock tumbled MarketWatch coverage
• Negative Sentiment: Market reaction and technicals — the Q4 miss pushed the shares to a 52‑week low and triggered heavy selling / elevated volume. 52‑week low report
• Negative Sentiment: Competitive risk — separate industry news that United Therapeutics is considering a new treprostinil formulation added pressure on related small‑cap biotech names, which may have weighed on sentiment. Competitive risk article

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.